ClinicalTrials.gg
CompletedNCT04526899Updated Jan 8, 2026Results posted

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

A Phase 2 interventional study of BNT111 and Cemiplimab in Melanoma Stage III, Melanoma Stage IV and Unresectable Melanoma, sponsored by BioNTech SE. Completed at 49 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by BioNTech SE · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing cemiplimab in Melanoma — 6 open to participants now, 9 under way, 1 of them phase 3. cemiplimab · Melanoma.

Enrollment
3rd of 11
184 · median 87
Started
2021
the only one that year
Phase 2
8 of 11
4 open now
Registered
3rd of 11
by date
Lead sponsor
1 of 11
BioNTech SE

Among the 11 studies testing cemiplimab in Melanoma, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 8 in phase 2, and was the 3rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 11 studies testing cemiplimab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cemiplimab in Melanoma, or all of them as a file.
02

Study summary

This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients will be randomized in a 2:1:1 ratio to Arm 1 (BNT111 + cemiplimab) and calibrator Arm 2 (BNT111 monotherapy), and Arm 3 (cemiplimab monotherapy). Patients in single agent calibrator arms (Arms 2 and 3), who experience centrally verified disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent.

03

Conditions studied

  • Melanoma Stage III
  • Melanoma Stage IV
  • Unresectable Melanoma

Browse trials for

Keywords

  • Cancer vaccine
  • Melanoma
  • Checkpoint inhibitor
  • Libtayo®
  • BNT111
  • Cemiplimab
  • RNA vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must sign the written form (ICF) before any screening procedure.
  • Patients must be aged >=18 years on the date of signing the informed consent.
  • Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the trial.
  • Patients must have confirmed unresectable Stage III or IV () cutaneous melanoma and by v1.1.
  • Patients must have confirmed disease progression on/after an approved /PD-L1 regimen for melanoma as defined by RECIST v1.1.

    1. Previous exposure to approved anti-PD-1/PD-L1 containing regimen for at least 12 consecutive weeks and
    2. Current radiological progression to be confirmed by two scans 4 to 12 weeks apart. If progression is accompanied by new symptoms, or deterioration of performance status not attributed to toxicity, one scan is sufficient and
    3. Inclusion into this trial must be within 6 months of confirmation of disease progression on anti-PD-1/PD-L1 treatment, regardless of any intervening therapy.
  • Patients should have received at least one but no more than five for advanced disease.
  • Patients must be able to tolerate additional anti-PD-1/PD-L1 therapy (i.e., did not permanently discontinue anti-PD-1/PD-L1 therapy due to toxicity).
  • Patients must have known B-Raf proto-oncogene (BRAF) mutation status.
  • Patients with BRAF V600-positive tumor(s) should have received prior treatment with a BRAF inhibitor (alone or in combination with a mitogen-activated protein kinase kinase [MEK] inhibitor).

    • Note: Considering the possible negative impact of a prior BRAF/MEK therapy on immune system targeting therapies, patients with BRAF V600-positive tumors with no tumor-related symptoms or evidence of rapid PD may be eligible for participation. This should be based on investigator assessment AND provided they are ineligible for, intolerant to, or have refused BRAF V600 mutation targeted therapy after receiving the information on possible other therapies including BRAF/MEK inhibitor-based therapy during the informed consent process.
  • Patients must have an performance status (PS) \<=1.
  • Adequate bone marrow function, as defined by hematological parameters (as defined in the protocol).
  • Patients must have serum lactate dehydrogenase \<= .
  • Patient should have adequate hepatic function, as defined in the protocol.
  • Patient should have adequate kidney function, assessed by the estimated >= 30 mL/min using the chronic kidney disease epidemiology collaboration equation.
  • Patient should be stable with adequate coagulation, as defined in the protocol.
  • Patients must provide the following samples:

    1. All patients: must provide a tumor tissue sample (formalin fixed paraffin-embedded [FFPE] blocks/slides) from a fresh biopsy collected before Visit Cycle1 Day1, or archival tissue. The archival tissue can be an FFPE block (not older than 3 years) or freshly cut slides (special storage conditions and immediate shipment to specialty lab are required), preferably derived from advanced disease stage.
    2. Patients at selected trial sites: After additional consent, patients must be amenable to pre-treatment and on-treatment peripheral blood mononuclear cell (PBMC) sampling and optional biopsy. If amenable, patients should provide a PBMC sample and optionally a biopsy which contains tumor tissue after failure/stop of last prior trial treatment.
  • Women of (WOCBP) must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at screening. Patients that are or permanently sterilized can be considered as not having . Female patients of reproductive potential must agree to use highly effective during and for 6 months after the last trial drug administration.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial starting at screening, during the trial and for 6 months after receiving the last trial treatment.
  • A man who is sexually active with a WOCBP and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 6 months after receiving the last trial treatment.

Exclusion Criteria:

  • Patients must not be pregnant or breastfeeding.
  • Patients must not have history of uveal, acral, or mucosal melanoma.
  • Patients must have no ongoing or recent evidence (within the last 5 years) of significant disease that required treatment with systemic treatments which may pose a risk for irAEs.

    • Note: Patients with autoimmune-related hyperthyroidism, autoimmune-related hypothyroidism who are in remission, or on a stable dose of thyroid-replacement hormone, vitiligo, or psoriasis may be included.
  • Patients must have no known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T cell-negative severe combined immunodeficiency [SCID]) or combined T and B cell immunodeficiencies (e.g., T and -B negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
  • Patients with uncontrolled type 1 diabetes mellitus or with uncontrolled adrenal insufficiency are not eligible.
  • Patients must have no uncontrolled infection with (HIV), or infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection. Mild cancer-related immunodeficiency (such as immunodeficiency treated with gamma globulin and without chronic or recurrent infection) is allowed.

    1. Patients with known HIV who have controlled infection (undetectable viral load and above 350 either spontaneously or on a stable anti-viral regimen) are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards.
    2. Patients with known hepatitis B virus (HBV) who have controlled infection (serum hepatitis B virus DNA polymerase chain reaction (PCR) that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA per local standards. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of trial treatment.
    3. Patients who are known hepatitis C virus (HCV) antibody positive who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
    4. Patients with HIV or hepatitis must have their disease reviewed by the specialist (e.g., infectious disease specialist or hepatologist) managing this disease prior to commencing and throughout the duration of their participation in the trial.
  • Patients with another primary that has not been in complete remission for at least 2 years, with the exception of those with a negligible risk of metastasis, progression or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, non-invasive, superficial bladder cancer or breast ductal carcinoma in situ).
  • Current use or use within 3 months prior to trial enrollment of systemic immune suppression including:

    1. use of chronic systemic medication (up to 5 mg/day prednisolone equivalent is allowed); patients using physiological replacement doses of prednisone for adrenal or pituitary insufficiency are eligible,
    2. other clinically relevant systemic immune suppression.
  • Treatment with other anti-cancer therapy including chemotherapy, radiotherapy, , or biological cancer therapy within 3 weeks prior to the first dose of trial treatment (6 weeks for nitrosureas). Adjuvant hormonotherapy used for breast cancer in long term remission is allowed.
  • Current evidence of ongoing National Cancer Institute version 5.0 (NCI-CTCAE v5.0) Grade > 1 toxicity of prior therapies before the start of treatment, with the exception of hair loss, hearing loss, Grade 2 peripheral neuropathy, or laboratory abnormalities not considered clinically significant per investigator's discretion, and those Grade 2 toxicities listed as permitted in other eligibility criteria.
  • Patients who have a local infection (e.g., cellulitis, abscess) or systemic infection (e. g., pneumonia, septicemia) which requires systemic antibiotic treatment within 2 weeks prior to the first dose of trial treatment.
  • Patients who have had a splenectomy.
  • Patients who have had major surgery (e.g., requiring general anesthesia) within 4 weeks before screening, have not fully recovered from surgery, or have a surgery planned during the time of trial participation.
  • Current evidence of new or growing brain or spinal metastases during screening. Patients with are excluded. Patients with known brain or spinal metastases may be eligible if they:

    1. had radiotherapy or another appropriate therapy for the brain or spinal bone metastases,
    2. have no neurological symptoms that can be attributed to the current brain lesions,
    3. have stable brain or spinal disease on the computed tomography or magnetic resonance imaging scan within 4 weeks before randomization (confirmed by stable lesions on two scans at least 4 weeks apart, the second scan can be carried out during screening),
    4. do not require steroid therapy within 14 days before the first dose of trial treatment,
    5. spinal bone metastases are allowed, unless imminent fracture or cord compression is anticipated.
  • History or current evidence of significant cardiovascular disease including, but not limited to:

    1. angina pectoris requiring anti-anginal medication, uncontrolled cardiac arrhythmia(s), severe conduction abnormality, or clinically significant valvular disease,
    2. (F) prolongation > 480 ms,
    3. arterial thrombosis or pulmonary embolism within ≤ 6 months before the start of treatment,
    4. myocardial infarction within ≤ 6 months before the start of treatment,
    5. pericarditis (any NCI-CTCAE grade), pericardial effusion (NCI-CTCAE Grade >= 2), non-malignant pleural effusion (NCI-CTCAE Grade >=2) or malignant pleural effusion (NCI-CTCAE Grade >= 3) within \<= 6 months before the start of treatment,
    6. Grade >= 3 symptomatic congestive heart failure (CHF) or (NYHA) criteria Class >= II within \<=6 months before the start of treatment.
  • Patients who have received a within 28 days of planned start of trial therapy.
  • Known to the active substances or to any of the .
  • Presence of a severe concurrent illness or other condition (e.g., psychological, family, sociological, or geographical circumstances) that does not permit adequate follow-up and compliance with the protocol.
  • Prior treatment with BNT111 and/or with cemiplimab.

Inclusion criteria for entering add-on therapy

  • Patients must have confirmed disease progression on monotherapy in Arm 2 or 3 of the trial.

    1. An initial radiological progression needs to be verified by BICR.
    2. Radiological progression to be confirmed by two scans 4 to 12 weeks apart unless initial progression is accompanied by new symptoms, or deterioration of PS not attributed to toxicity, in which case one scan is sufficient.
  • Patients must sign a new ICF to continue with add-on therapy. Informed consent must be documented before any add-on-specific procedure is performed.
  • WOCBP must have a negative serum (beta-hCG) at baseline. Patients that are postmenopausal or permanently sterilized can be considered as not having reproductive potential.
  • Female patients of reproductive potential must agree to use adequate contraception during and for 6 months after the last trial drug administration.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial starting at screening, during the trial and for 6 months after receiving the last trial treatment.
  • A man who is sexually active with a WOCBP and has not had a vasectomy must agree to use a barrier method of birth control, e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 6 months after receiving the last trial treatment.

Exclusion criteria for entering add-on therapy

  • Prior toxicity related to trial medication should have resolved to NCI-CTCAE v5.0 Grade ≤ 1 before the start of add-on treatment and may not have led to permanent discontinuation.
  • The time between confirmed PD on monotherapy and start of add-on therapy shall not exceed 6 weeks.
  • Current evidence of new or growing brain or spinal metastases at baseline (lesions that remained stable during initial treatment are allowed).
  • Systemic immune suppression:

    1. use of chronic systemic steroid medication (up to 5 mg/day prednisolone equivalent is allowed); patients using physiological replacement doses of prednisone for adrenal or pituitary insufficiency are eligible,
    2. other clinically relevant systemic immune suppression.
  • Presence of cardiovascular, renal, hepatic or any other disease that in the investigator's opinion, may increase the risks associated with trial participation or require treatments that may interfere with the conduct of the trial or the interpretation of trial results.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    BNT111 + cemiplimab

    Biological: BNT111 · Biological: Cemiplimab

  • Experimental
    BNT111 monotherapy

    Biological: BNT111

  • Experimental
    Cemiplimab monotherapy

    Biological: Cemiplimab

Interventions

  • BiologicalBNT111

    IV injection

  • BiologicalCemiplimab

    IV infusion

06

What researchers measure

Primary outcomes

  1. Arm 1: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants in whom a complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) was observed as best overall response by blinded independent central review (BICR). Per RECIST 1.1 criteria, CR defined as the disappearance of all target lesions and PR was defined as the \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Up to 24 months

Secondary outcomes

  1. Arms 2 & 3: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 Months

  2. Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR)

    DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 Months

  3. Disease Control Rate (DCR) As Assessed by BICR

    DCR is defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 months

  4. Time to Response (TTR) As Assessed by BICR

    TTR is defined as the time from randomization to the first objective tumor response (CR or PR) by BICR. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 months

  5. Progression-Free Survival (PFS) As Assessed by BICR

    PFS is defined as the time from randomization to first objective tumor progression (PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 Months

  6. Objective Response Rate (ORR) As Assessed by the Investigator

    ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 months

  7. Duration of Response (DOR) As Assessed by the Investigator

    DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 Months

  8. Disease Control Rate (DCR) As Assessed by the Investigator

    DCR defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 months

  9. Time to Response (TTR) As Assessed by the Investigator

    TTR is defined as the time from randomization to the first objective tumor response (CR or PR) as assessed by investigator. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 months

  10. Progression-Free Survival (PFS) As Assessed by the Investigator

    PFS is defined as the time from randomization to first objective tumor progression (PD) by investigator or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 24 Months

  11. Arm 1: Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 48 months

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) is defined as any AE with an onset date on or after the first administration of trial treatment (if the AE was absent before the first administration of trial treatment) or worsened after the first administration of trial treatment (if the AE was present before the first administration of trial treatment). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 27 months

  13. Number of Participants With Immune-Related Adverse Events (irAE)

    AEs related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 27 months

  14. Number of Participants Reporting Dose Reduction and Discontinuation Due to TEAE

    Participants with dose reduction and discontinuation due to TEAE will be reported. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 27 months

  15. Change From Baseline in Laboratory Parameters Values: Hematology: Basophils

    Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  16. Change From Baseline in Laboratory Parameters Values: Hematology: Eosinophils

    Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  17. Change From Baseline in Laboratory Parameters Values: Hematocrit

    Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  18. Change From Baseline in Laboratory Parameters Values: Hemoglobin

    Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  19. Change From Baseline in Laboratory Parameters Values: Hematology: Lymphocytes

    Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  20. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Albumin

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  21. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alkaline Phosphatase

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  22. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alanine Aminotransferase

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  23. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Amylase

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  24. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Aspartate Aminotransferase

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  25. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Bilirubin

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  26. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatine Kinase

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  27. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatinine

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  28. Change From Baseline in Laboratory Parameters Values: Clinical Chemistry: C-Reactive Protein

    Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  29. Change From Baseline in Laboratory Parameters Values: Coagulation Factors: Activated Partial Thromboplastin Time

    Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  30. Change From Baseline in Laboratory Parameters Values: Coagulation Factors: Prothrombin Time

    Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  31. Change From Baseline in Laboratory Parameters Values: Endocrine Tests: Thyroxine

    Blood samples will be collected for the assessment of endocrine tests. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  32. Change From Baseline in Laboratory Parameters Values: Urinalysis: pH

    Urine samples will be collected for the assessment of pH. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  33. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Participants with clinically significant abnormalities in laboratory parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 25 months

  34. Change From Baseline in Vital Signs Parameters: Systolic Blood Pressure

    Systolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  35. Change From Baseline in Vital Signs Parameters: Diastolic Blood Pressure

    Diastolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  36. Change From Baseline in Vital Signs Parameters: Heart Rate

    Heart rate (in beats per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  37. Change From Baseline in Vital Signs Parameters: Respiratory Rate

    Respiratory Rate (in breaths per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  38. Change From Baseline in Vital Signs Parameters: Body Temperature

    Body Temperature (in degree Celsius) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  39. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Participants with clinically significant abnormalities in vital sign parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 25 months

  40. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Total Score

    Mean change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Score will be reported. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Response to Global Health Status is measured on a 1 to 7 scale. "1" being very poor and "7" being excellent. Positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. Raw data was linearly transformed to be in a range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  41. Change From Baseline in EORTC QLQ-C30 Functional Scales Score

    The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening of symptoms. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  42. Changes From Baseline in EORTC QLQ-C30 Symptoms Scales Score

    The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Each scale (symptom scale \[pain, fatigue, and appetite loss\] and Global Health Status/Quality of Life \[QoL\] scale) was linearly transformed to be in range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: From Baseline up to 25 months

  43. Time to First Clinically Meaningful Deterioration in Global Health Status Score as Measured by EORTC QLQ-C30

    Time to first clinically meaningful deterioration in global health status score as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 25 months

  44. Time to First Clinically Meaningful Deterioration in Symptoms and Functioning as Measured by EORTC QLQ-C30

    Time to first clinically meaningful deterioration in symptoms and functioning as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.

    Time frame: Up to 25 months

07

Results

Posted Dec 15, 2025

Participant flow

In total,184 participants were randomized to treatment but 3 participants (2 participants in Arm 1 and 1 participant in Arm 3, respectively) did not receive the study treatment.

Participant flow — Overall Study
MilestoneArm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab Monotherapy
Started944644
Treated924643
Completed000
Not completed944644
Withdrew: Withdrawal by subject322
Withdrew: Lost to follow-up331
Withdrew: Investigator's decision100
Withdrew: Death331713
Withdrew: Other100
Withdrew: On-treatment191012
Withdrew: Survival follow-up341416

Outcome measures

PrimaryArm 1: Objective Response Rate (ORR)

ORR was defined as the percentage of participants in whom a complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) was observed as best overall response by blinded independent central review (BICR). Per RECIST 1.1 criteria, CR defined as the disappearance of all target lesions and PR was defined as the \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Arm 1: Objective Response Rate (ORR)
percentage of participantsArm 1: BNT111 + Cemiplimab
Arm 1: Objective Response Rate (ORR)18.0 (10.64 to 27.55)
Statistical analysis
  • Arm 1: BNT111 + Cemiplimab · 1-sided exact binomial test · p = 0.0148
SecondaryArms 2 & 3: Objective Response Rate (ORR)

ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 Months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR)

DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 Months

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR) As Assessed by BICR

DCR is defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by BICR. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryTime to Response (TTR) As Assessed by BICR

TTR is defined as the time from randomization to the first objective tumor response (CR or PR) by BICR. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS) As Assessed by BICR

PFS is defined as the time from randomization to first objective tumor progression (PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 Months

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR) As Assessed by the Investigator

ORR is defined as the percentage of participants in whom a CR or PR according to RECIST v1.1 observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) As Assessed by the Investigator

DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease, PD) by BICR or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 Months

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR) As Assessed by the Investigator

DCR defined as the percentage of participants in whom a CR, PR or stable disease (SD; assessed at least 6 weeks after first dose) is observed as best overall response by investigator. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryTime to Response (TTR) As Assessed by the Investigator

TTR is defined as the time from randomization to the first objective tumor response (CR or PR) as assessed by investigator. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS) As Assessed by the Investigator

PFS is defined as the time from randomization to first objective tumor progression (PD) by investigator or death from any cause (whichever occurs first). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 24 Months

Results for this outcome have not been posted.

SecondaryArm 1: Overall Survival (OS)

OS is defined as the time from randomization to death from any cause. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 48 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

A treatment-emergent adverse event (TEAE) is defined as any AE with an onset date on or after the first administration of trial treatment (if the AE was absent before the first administration of trial treatment) or worsened after the first administration of trial treatment (if the AE was present before the first administration of trial treatment). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 27 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Immune-Related Adverse Events (irAE)

AEs related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 27 months

Results for this outcome have not been posted.

SecondaryNumber of Participants Reporting Dose Reduction and Discontinuation Due to TEAE

Participants with dose reduction and discontinuation due to TEAE will be reported. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 27 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Hematology: Basophils

Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Hematology: Eosinophils

Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Hematocrit

Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Hemoglobin

Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Hematology: Lymphocytes

Blood samples will be collected for the assessment of hematology parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Albumin

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alkaline Phosphatase

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Alanine Aminotransferase

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Amylase

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Aspartate Aminotransferase

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Bilirubin

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatine Kinase

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: Creatinine

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Clinical Chemistry: C-Reactive Protein

Blood samples will be collected for the assessment of clinical chemistry parameters. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Coagulation Factors: Activated Partial Thromboplastin Time

Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Coagulation Factors: Prothrombin Time

Blood samples will be collected for the assessment of coagulation factors. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Endocrine Tests: Thyroxine

Blood samples will be collected for the assessment of endocrine tests. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Laboratory Parameters Values: Urinalysis: pH

Urine samples will be collected for the assessment of pH. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Participants with clinically significant abnormalities in laboratory parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Vital Signs Parameters: Systolic Blood Pressure

Systolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Vital Signs Parameters: Diastolic Blood Pressure

Diastolic blood pressure (in mmHg) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Vital Signs Parameters: Heart Rate

Heart rate (in beats per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Vital Signs Parameters: Respiratory Rate

Respiratory Rate (in breaths per minute) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Vital Signs Parameters: Body Temperature

Body Temperature (in degree Celsius) will be assessed. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Participants with clinically significant abnormalities in vital sign parameters will be reported. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Total Score

Mean change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (EORTC QLQ-C30) Global Health Status Score will be reported. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Response to Global Health Status is measured on a 1 to 7 scale. "1" being very poor and "7" being excellent. Positive changes indicated better health status or functioning, and negative changes indicated worsening of health status or functioning. Scale scores range from 0 to 100. Raw data was linearly transformed to be in a range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in EORTC QLQ-C30 Functional Scales Score

The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. EORTC QLQ-C30 Physical Functioning Score is a questionnaire to assess quality of life of cancer patients. It is composed of 30 items, multi-item measure (28 items) and 2 single-item measures. For the multiple item measure, 4-point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening of symptoms. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryChanges From Baseline in EORTC QLQ-C30 Symptoms Scales Score

The EORTC QLQ-C30 questionnaire incorporates nine multi-item scales: 5 functional scales (physical, cognitive, role, emotional, and social); 3 symptom scales (pain, fatigue, and appetite loss) and a Global Health Status/QoL scale. Each item, except Global Health Status, is answered on a four-point scale (1-4): 1-not at all, 2-a little, 3-quite a bit, 4-very much. Each scale (symptom scale \[pain, fatigue, and appetite loss\] and Global Health Status/Quality of Life \[QoL\] scale) was linearly transformed to be in range from 0-100 where a higher score represents good health status, while lower scores indicate poor health status. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
From Baseline up to 25 months

Results for this outcome have not been posted.

SecondaryTime to First Clinically Meaningful Deterioration in Global Health Status Score as Measured by EORTC QLQ-C30

Time to first clinically meaningful deterioration in global health status score as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 25 months

Results for this outcome have not been posted.

SecondaryTime to First Clinically Meaningful Deterioration in Symptoms and Functioning as Measured by EORTC QLQ-C30

Time to first clinically meaningful deterioration in symptoms and functioning as measured by EORTC QLQ-C30 will be reported. Data for this outcome measure will be reported at the time of final results posting.

Time frame:
Up to 25 months

Results for this outcome have not been posted.

Adverse events

Collected over From Baseline until last dose of study treatment (up to 25 months). As per protocol, non-serious adverse events (AEs) with an onset date more than 90 days after last administration of study treatment are only reported below if assessed as related to investigational medicinal product by investigator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: BNT111 + Cemiplimab33/94 (35.1%)30/92 (32.6%)89/92 (96.7%)
Arm 2: BNT111 Monotherapy6/46 (13%)8/46 (17.4%)43/46 (93.5%)
Arm 3: Cemiplimab Monotherapy6/44 (13.6%)11/43 (25.6%)33/43 (76.7%)
Add-on Treatment: BNT111 + Cemiplimab (add-on)11/25 (44%)6/25 (24%)22/25 (88%)
Add-on Treatment: Cemiplimab + BNT111 (add-on)7/22 (31.8%)7/22 (31.8%)22/22 (100%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventArm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyAdd-on Treatment: BNT111 + Cemiplimab (add-on)Add-on Treatment: Cemiplimab + BNT111 (add-on)
Disease progressionGeneral disorders8/921/463/433/252/22
AnaemiaBlood and lymphatic system disorders1/920/463/430/250/22
Cytokine release syndromeImmune system disorders5/920/460/430/251/22
Subcutaneous abscessInfections and infestations0/920/462/430/250/22
General physical health deteriorationGeneral disorders0/920/460/430/251/22
Abscess limbInfections and infestations0/920/461/430/251/22
Pneumonia bacterialInfections and infestations0/920/460/430/251/22
Infusion related reactionInjury, poisoning and procedural complications1/920/460/430/251/22
ProstatomegalyReproductive system and breast disorders0/920/460/430/251/22
HaemothoraxRespiratory, thoracic and mediastinal disorders0/920/460/430/251/22
Most frequent other events
Showing 10 of 54
Most frequent other events
EventArm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyAdd-on Treatment: BNT111 + Cemiplimab (add-on)Add-on Treatment: Cemiplimab + BNT111 (add-on)
PyrexiaGeneral disorders66/9235/462/4312/2517/22
ChillsGeneral disorders45/9224/462/435/2514/22
NauseaGastrointestinal disorders34/9211/466/433/255/22
AstheniaGeneral disorders13/927/466/438/257/22
HypotensionVascular disorders9/928/461/430/256/22
VomitingGastrointestinal disorders23/926/465/433/254/22
FatigueGeneral disorders22/927/462/435/252/22
Influenza like illnessGeneral disorders20/9210/460/432/251/22
AnaemiaBlood and lymphatic system disorders11/924/465/432/254/22
C-reactive protein increasedInvestigations1/921/466/432/254/22

Baseline characteristics

Analysis was performed on intent to treat (ITT) set that included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Arm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyTotal
Mean62.9 ± 13.5463.1 ± 13.8961.9 ± 15.7862.7 ± 14.12
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyTotal
Female34171970
Male602925114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyTotal
Hispanic or Latino3227
Not Hispanic or Latino854141167
Unknown or Not Reported63110
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: BNT111 + CemiplimabArm 2: BNT111 MonotherapyArm 3: Cemiplimab MonotherapyTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American00000
White894444177
More than one race0000
Unknown or Not Reported5207
08

Study locations

49 sites
  • University Of Arizona College Of Medicine
    Tucson, Arizona 85724, United States
  • University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158-3214, United States
  • Sylvester Comprehensive Cancer Center/ UMHC
    Miami, Florida 33136, United States
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists
    Omaha, Nebraska 68310, United States
  • Atlantic Health System / Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • Inova Dwight and Martha Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Border Medical Oncology
    East Albury, 2640, Australia
  • Gold Coast Hospital
    Southport, 4215, Australia
  • Melanoma Institute Australia
    Sydney, 2060, Australia
  • Klinik für Dermatologie, Dermatochirurgie, Allergologie, Klinikum Bremen-Ost, Gesundheitnord GmbH
    Bremen, 28325, Germany
  • Universitätsklinikum Essen (AoR)
    Essen, 45147, Germany
  • Universitätsklinikum Freiburg, Klinik füer Dermatologie und Venerologie
    Freiburg im Breisgau, 79104, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel Hautkrebszentrum Kiel
    Kiel, 24105, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitätsmedizin der Johannes Gutenberg Universität Mainz KoeR
    Mainz, 55131, Germany
  • Universitätsklinikum Mannheim GmbH
    Mannheim, 68167, Germany
  • Klinikum Nürnberg Nord
    Nuremberg, 90419, Germany
  • University Hospital Tübingen
    Tübingen, 72076, Germany
  • Klinikum der Julius-Maximilians-Universität Würzburg
    Würzburg, 97080, Germany
  • Istituto Di Ricovero E Cura A Carattere Scientifico - Istituto Tumori Giovanni Paolo Ii
    Bari, 70124, Italy
  • Azienda ospedaliera universitaria Bologna
    Bologna, 40138, Italy
  • Fondazione del Piemonte per l'Oncologia, Istituto di Candiolo (IRCCs)
    Candiolo, 10060, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumpori (IRST)
    Meldola, 47014, Italy
  • Istituto Nazionale Tumori Fondazione Pascale - IRCCS · S.C. Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative
    Naples, 80131, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS
    Padova, 35128, Italy
  • Policlinico Universitario Campus Bio-Medico
    Rome, 00128, Italy
  • Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte
    Siena, 53100, Italy
  • AOU Citta della Salute e della Scienza di Torino
    Turin, 10126, Italy
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80214, Poland
  • Szpital Specjalistyczny im. Luwika Rydygiera w Krakowie Sp. z o.o.
    Krakow, 31-826, Poland
  • Zachodniopomorskie Centrum Onkologii
    Szczecin, 71-730, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
    Warsaw, 02-781, Poland
  • Hospital Teresa Herrera (CHUAC)
    A Coruña, 15009, Spain
  • Hospital Universitari Germans Trias i Pujol (HUGTP)
    Badalona, 8916, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital De La Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Institut Català d'Oncologia l'Hospitalet
    Barcelona, 08907, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, 30120, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, 28222, Spain
  • Hospital Universitario Marques De Valdecilla
    Santander, 39008, Spain
  • Complejo Hospitalario Universitario De Santiago De Compostela
    Santiago de Compostela, 15706, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
  • Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)
    Valencia, 46026, Spain
  • Beatson West of Scotland Cancer Centre - Greater Glasgow Health Board
    Glasgow, G12 0YN, United Kingdom
  • The Christie - The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Royal Cornwall Hospital
    Truro, TR1 3LJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jan 2024, 32 months.

Results were first posted in Dec 2025, 1 year 10 months after primary completion. A results delay was requested in Jan 2025.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 32 months is close to that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 26, 2020
StartActual
May 19, 2021
Primary completionActual
Jan 25, 2024
CompletionActual
Nov 24, 2025
Results delay requested
Jan 23, 2025
Results first posted
Dec 15, 2025
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04526899
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Aug 26, 2020
Start date
May 19, 2021
Primary completion
Jan 25, 2024
Completion
Nov 24, 2025
Results posted
Dec 15, 2025
Last update
Jan 8, 2026

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion